A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Trial Details

NCT ID

NCT06568094

Phase

PHASE1 / PHASE2

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• HRS-5041 tablets
• Abiraterone Acetate tablets（II）
• Prednisone Acetate tablets
• Docetaxel Injection
• HRS-1167 tablets
• SHR2554 tablets

Locations (sample)

• Harbin, Heilongjiang, China|45.75,126.65
• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Have the ability to give informed consent, and are willing and able to comply with planned visits for medical examinations and other procedural req…
• The age is above 18 years old when signing the informed consent (the ceiling age is 80 years old in the dose escalation phase), male.
• ECOG score is 0 or 1.
• An expected survival of ≥ 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.